STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] CapsoVision, Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

CapsoVision, Inc. appointed David Garcia as principal financial officer and principal accounting officer, effective November 3, 2025. Garcia brings more than 20 years of finance leadership experience, most recently serving as VP of Financial Planning and Analysis at Matterport from October 2020 to October 2025, with prior senior roles at View, Intelepeer, and Align Technology.

His compensation includes a $300,000 annual base salary, an option to purchase 165,000 shares granted on November 3, 2025 at the closing share price that day, and a $12,500 quarterly bonus. Vesting is structured with 25% on November 3, 2026, and the remainder in 36 equal monthly installments thereafter. The company entered into its standard indemnification agreement with Garcia. The company reported no arrangements leading to his appointment and no related-party relationships under Item 404(a). A press release announcing the appointment was furnished as Exhibit 99.1.

Positive
  • None.
Negative
  • None.

Insights

Executive appointment with standard comp; neutral governance event.

CapsoVision named David Garcia as principal financial and accounting officer, effective November 3, 2025. The filing outlines a typical compensation package: $300,000 base salary, option for 165,000 shares at the grant-date close, and a $12,500 quarterly bonus. The vesting schedule (25% after one year, then 36 monthly installments) aligns with retention-focused equity structures.

The company states no arrangements or family relationships related to the appointment and references its standard indemnification agreement. A press release was furnished under Item 7.01. From an investment lens, this is administrative; impact depends on Garcia’s execution, which is not evaluated here.

FALSE000137832500013783252025-11-032025-11-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2025
_________________________
CapsoVision, Inc.
(Exact name of registrant as specified in its charter)
_________________________
Delaware001-4270520-3369494
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
18805 Cox Avenue, Suite 250
Saratoga, California
95070
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (408)-624-1488
n/a
(Former Name or Former Address, if Changed Since Last Report)
_________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol
Name of each exchange
on which registered
common stock, $0.001 par value per shareCVThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Item 5.02.           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of November 3, 2025, David Garcia, Senior VP of Finance of CapsoVision, Inc. (the “Company”), has been appointed by the board of directors of the Company (the “Board”) to serve as the Company’s principal financial officer and principal accounting officer. Mr. Garcia, age 51, has more than 20 years of financial leadership experience and most recently served as Vice President of Financial Planning and Analysis at Matterport, Inc. from October 2020 through October 2025. Mr. Garcia has also held senior finance roles at View, Inc., Intelepeer Cloud Communications, and Align Technology.
In connection with Mr. Garcia’s appointment, the Compensation Committee of the Board approved an annual base salary of $300,000, and the grant to Mr. Garcia on November 3, 2025 of a stock option to purchase 165,000 shares of the Company’s common stock under the Company’s 2025 Equity Incentive Plan. The per share exercise price of the option equals the closing price per share of the Company’s common stock on November 3, 2025. Twenty-five percent (25%) of the option is scheduled to vest and become exercisable on November 3, 2026. The remaining portion of the option is scheduled to vest and become exercisable in thirty-six (36) equal monthly installments on the same day of each successive calendar month following November 3, 2026. Mr. Garcia will also be eligible to receive a quarterly bonus of $12,500.
The Company has also entered into its standard indemnification agreement with Mr. Garcia, the form of which was previously filed by the Company as Exhibit 10.11 to the Registration Statement on Form S-1/A (File No. 333-287148), initially filed by the Company with the SEC on June 13, 2025, and is incorporated herein by reference.
There are no arrangements or understandings between Mr. Garcia and any other person pursuant to which Mr. Garcia was appointed as principal financial officer and principal accounting officer and there are no family relationships between Mr. Garcia and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item. 7.01 Regulation FD Disclosure.

On November 3, 2025, the Company issued a press release announcing the appointment of Mr. Garcia as principal financial officer and principal accounting officer of the Company. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the “Securities Act”), unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.
Item 9.01.           Financial Statements and Exhibits.
The following exhibits are being filed herewith:
Exhibit
No.
Description
99.1
Press Release of CapsoVision, Inc, dated November 03, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CAPSOVISION, INC.
Date: November 3, 2025By:/s/ Kang-Huai (Johnny) Wang
Name:Kang-Huai (Johnny) Wang
TitlePresident and Chief Executive Officer

CapsoVision, Inc.

NASDAQ:CV

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

223.58M
5.25M
40.69%
0.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA